Company Profile

Company Overview

Verseau Therapeutics is a multifaceted platform company with a broad focus on macrophages in human disease. The platform is built around a discovery engine combining computational approaches with original validation assays based on human samples. The Verseau pipeline will combine monoclonal antibodies, small molecules, and novel therapeutic modalities using nucleic-acid-carrying lipid nanoparticles. The company holds IP from MIT laboratories of Robert Langer and Daniel Anderson and has internal know-how around methods of delivery to macrophages. The early application of our platform is in cancer. The goal is to complement current approved therapies based on T cell checkpoint inhibitors and to broaden immune therapy utility by activating immune response to tumors with no prior T cell reactivity. Our goal is to build a leading biopharmaceutical brand with focus on macrophage-based therapies in a broad spectrum of disease indications.